Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.
It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.
As the UK and a number of European countries are now experiencing epidemics of influenza, including A(H1N1) which was the 2009 pandemic virus, the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) warns that the consequences of non-vaccination could emerge as a new flu emergency and are calling for greater efforts to encourage vaccination, not only for at risk groups but also health care workers.
Parents of kids returning to school in the UK after Christmas holidays have been warned of a surge in flu cases. Professor John Oxford, a leading virologist at St Bartholomew’s and the Royal London Hospital explained that children returning to school in the past prompted a rise in the number of flu cases. “You tend to get a surge,” the professor said. “I would anticipate a surge, but how long that will last is difficult to say.” He added, “This virus is not going to go away next week. Even if it’s already peaked, it’s still going to be around for the next couple of weeks and it’s still worthwhile being vaccinated at this stage.”
A complimentary planning tool is now available to help the nation's nursing homes prepare for an influenza pandemic. The new resource is courtesy of the New Jersey Hospital Association, with grant funding from Hoffman-LaRoche.
The flu season continues to affect more people. Experts have warned the Britons are still at risk as the surge in flu cases has still not yet peaked. The cases would increase they warn, over the next two to four weeks. World Health Organization released figures that show the rate of influenza-like illnesses is still low across continental Europe but has risen dramatically in Britain since the flu season began in October.
SinoFresh® HealthCare, Inc., is pleased to announce that its marketing division has secured an agency marketing relationship with Green Valley Drug, the largest medical supplier in Southern Nevada with a significant pharmacy and medical customer base in the western U.S.
As number of cases of flu rise in the UK, Health Secretary Andrew Lansley is under pressure to strengthen the flu vaccination campaign. He reinstated a public health “Catch It, Bin It, Kill It” advertising campaign after he was warned by government advisers of the need to improve immunization rates which are at their lowest this winter for many years. It had been discontinued despite helping educate the public to adopt good hygiene habits during last year’s H1N1 swine flu epidemic at a cost of just £609,000. There were 12 more deaths in the last week from flu, bringing the total this winter to 39, the Health Protection Agency (HPA) said today. Thirty-six were killed by H1N1 swine flu, which is the most virulent of the two main flu strains currently circulating. The others died after contracting Influenza B, the other strain. All except one of the 39 were under 65 and four were under five.
CEL-SCI Corporation announced today that it has commenced its Phase III clinical trial for Multikine®, the Company's flagship immunotherapy. CEL-SCI has now completed all of the manufacturing and regulatory requirements to begin enrollment of the study.
Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today that it received approval from the China State Food and Drug Administration (SFDA) to commence clinical trials for its proprietary inactivated EV71 vaccine against Hand, Foot and Mouth Disease (HFMD).
Figures reveal that the rates of flu infection in the UK have more than doubled in the last week. Number of cases has risen to 87.1 per 100,000 people, from 32.8 in the previous week, according to the Royal College of GPs. Reports also reveal that school-age children from England and Wales are particularly affected. Ages five to 14 are highest affected followed by those under four, then people aged 15 to 44. Considering all age groups rates almost tripled in the South in one week, from 36 per 100,000 to 93.4. In the North, the rate was 55.5, up from 15.7, and was 94.9 in the central England region, up from 37.9.
Scientific American examines how, in an attempt to improve early recognition of viruses that could give rise to pandemics in people, such as last year's H1N1 swine flu, scientists are looking to better understand "the viruses that infect the estimated 941 million domesticated pigs around the world." However, as the article notes, "[i]ntensive monitoring of pig viruses is unlikely to come any time soon … Most pork-producing countries do not test their pigs at all, and in some that do - such as the U.S. - the testing is done on behalf of the pork producers.
Novavax, and scientists at the University of Massachusetts Medical School, led by Dr. Trudy Morrison, published in the January 2011 issue of The Journal of Virology, a report indicating that a novel virus-like particle vaccine candidate against respiratory syncytial virus (RSV) protects mice from a live virus challenge.
Walgreens announced record earnings and sales for the first quarter of fiscal year 2011.
NanoViricides, Inc., announced today that it had consummated a closing with Seaside 88, LP ("Seaside"), a Florida limited partnership, on Seaside's purchase of an additional $2.5M of the Company's Series B Convertible Preferred Stock. Seaside has financed several leading-edge bio-pharma companies, including Cytori Therapeutics, Inc., Generex Biotechnology Corporation, and NovaDel Pharma, Inc. among others.
Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it has demonstrated the ability to capture immunosuppressive exosomes derived from individuals with lymphoma and colorectal cancer.
Mount Sinai School of Medicine today announced that the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has renewed funding of the Program for Research on Immune Modeling and Experimentation. This program seeks to develop easy-to-use, predictive mathematical models to better understand patterns of infection among individuals affected by the H1N1 and 1918 influenza viruses and other related viruses.
CEL-SCI Corporation announced today it has received governmental approval from the Health Authority, Ministry of Health of Ukraine, to begin enrollment of subjects for a Phase III clinical trial of Multikine® in Ukraine. Multikine is the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer. Ukraine is one of nine countries to participate in this global Phase III trial. The Phase III trial will be run at about 48 clinical centers, of which about 6 centers will be in Ukraine.
Carrageenan, is a polymer derived from red seaweed which helps to create a protective physical barrier in the nasal cavity and has proven to be an effective antiviral in the treatment of the common cold.
Bresslergroup, an award-winning new product development firm, has designed a unique device that allows a person to easily disinfect an entire room without labor or hazardous chemicals.
Results from a government-sponsored clinical trial of inactivated 2009 H1N1 influenza vaccine in people with asthma indicate that a single dose of vaccine was safe and induced a strong immune response predictive of protection.
CEL-SCI Corporation reported financial results today for the fiscal year ended September 30, 2010.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.